Chronic critical limb ischemia (CLI) is defined as the end stage of lower limb ischemia due to peripheral arterial disease (PAD). The prognosis of CLI patients is poor with an 1-year major amputation rate of 30%.
On the basis of numerous successful animal experiments, cell therapies for PAD using bone marrow-derived mononuclear cells (BM-MNCs), [3] [4] [5] [6] [7] peripheral bloodderived mononuclear cells (PB-MNCs), 8, 9) and adiposederived stem cells (ADSCs) 1, 10) have been reported to be promising, though more evidence needs to be accumulated before being used as a standard modality of treatment.
Among the various sources of stem or progenitor cells, adipose tissue represents an attractive source of autologous adult stem cells used in regenerative therapy owing to its abundance, surgical accessibility, and high content of multipotent mesenchymal stem cell (MSC)-like cells.
11) It has been reported that the adipose tissue yields far more colony-forming units than the bone marrow when the weight of the tissues used is the same.
12) However, knowledge of the cellular origin of culture-expanded mesenchymal-like ADSCs remains elusive because of the complex organization of stromal cells surrounding the small blood vessels. 13) Recent studies have suggested that the perivascular niche may be an important reservoir of MSCs in multiple developed organs. 14, 15) While it is evident that not all perivascular cells are MSCs, the majority of MSCs are believed to reside in the perivascular area. 16) Although there are no specific cell surface markers for perivascular cells or pericytes that regulate vessel stability and vascular survival, platelet-derived growth factor receptor beta (PDGFRβ) is thought to be a major cell surface marker defining the pericytes. 17, 18) We hypothesized that PDGFRβ-positive (PDGFRβ+) perivascular cells of the white adipose tissue from CLI patients would have characteristics of the MSCs and would be a good source for autologous cell transplantation as a treatment for CLI.
The purposes of our study were (1) to identify PDGFRβ+ perivascular cells in the white adipose tissue from CLI patients; (2) to isolate and characterize PDGFRβ+ cells from the stromal vascular fraction (SVF) of patient's adipose tissue in vitro; and (3) to investigate the differentiation potential of PDGFRβ+ cells as a reliable source of MSCs that can be used for the treatment of CLI.
METHODS

Acquisition of the Fresh Subcutaneous Human Adipose Tissues and Preparation of the SVF
This study was approved by Seoul National University Hospital Institutional Review Board (No. 1103-035-354) and informed consent was obtained from all patients. Among the 28 patients who had undergone lower limb amputation surgery (below knee amputation or above knee amputation) due to CLI from March 2010 to September 2011, 10 specimens from 10 patients were included in this study. The other 18 patients declined to participate and were excluded. Subcutaneous adipose tissue (1-3 g) was obtained aseptically from each amputated specimen and transported to our laboratory in aseptic bottles with phosphate buffered saline (PBS). Medical records were not profiled in accordance with IRB instructions as they could be used for the identification of tissue donors. Samples from three patients were allocated to immunofluorescence staining of fresh fat tissue and fluorescence-activated cell sorter (FACS) analysis of fresh SVF and remaining 7 samples were used after expansion to obtain enough amount of cells for extensive FACS analysis (triple samples for each analysis).
The SVF of adipose tissue was isolated as described in previous studies. [19] [20] [21] Fresh fat tissues were washed at least three times with PBS to remove blood, and then digested at 37°C for 1 hour with 0.075% collagenase type 1 (Sigma-Aldrich, St. Louis, MO, USA) in Dulbecco's Modified Eagle Medium (DMEM; Gibco, New York, NY, USA). Mature adipocyte fractions were separated from stromal fractions by centrifuging at 1,200 × g for 10 minutes. The remained fractions were treated with red blood cell lysis buffer for 10 minutes at room temperature (RT) and then filtered through 100-μm nylon mesh to exclude remaining erythrocyte debris, and then centrifuged at 1,200 × g for 10 minutes.
Immunofluorescence of the Fresh Fat Tissue
Pieces of harvested adipose tissues were washed in PBS, 10% formalin (Sigma-Aldrich), and held for at least 24 hours at 4°C, before being embedded in paraffin. Sections (6 to 8 μm) were cut on a rotary microtome (Leica RM2145, Leica Microsystems, Nussloch, Germany) fixed for 1 hour at 56°C, and then stored at RT. Before staining, sections were deparaffinized in xylenes. Tissue rehydration and all subsequent washes were performed by 25-minute incubations in a Zytomed wash buffer (Zytomed systems GmbH, Berlin, Germany). All incubations were completed at ambient temperature. For fluorescent immuno-staining, rehydrated tissue sections were pretreated with protein blocking in serum-free protein blocks (Dako, Glostrup, Denmark) and incubated with antibodies for 2 hours. Nuclear staining was attained through 10-minute incubation with Hoechst 33258 (Invitrogen, Carlsbad, CA, USA). Slides were mounted in Histomount (National Diagnostics, Atlanta, GA, USA), and observed under a fluorescence microscopy (BX61; Olympus, Tokyo, Japan) and a digital imaging system (DCF 500; Leica Microsystems).
Antibodies used in these studies were anti-CD140b (PDGFRβ, 1:50; BD Biosciences, San Jose, CA, USA), anti-CD146 (1:50; R&D Systems, Minneapolis, MN, USA), anti-CD90 (1:100; BD Biosciences), and anti-CD31 (1:100; BD Biosciences). All antibodies were diluted in an antibody diluent with background reducing components (Dako).
Analysis of Cell Surface Antigen Profile of the Fresh SVF Cells and Culture Expansion of Fluorescence-Activated Cell Sorted PDGFR-Positive Cells
Cell surface antigen profiles of freshly isolated SVF cells were quantified by flow cytometry with a FACS. 13, 22, 23) Fat tissue was thoroughly minced with scissors and digested for 30 minutes in DMEM and 0.075% collagenase type I (Sigma Aldrich) on a rotator at 37°C. Mature adipocytes were eliminated by centrifugation (1,200 × g, ambient temperature, 10 minutes) and cell pellets were resuspended in blood cell lysis buffer, incubated for 10 minutes at RT and washed in PBS.
Freshly isolated cells from the SVF were maintained on ice, and stained for analytical flow cytometry and cell sorting experiments as previously described. 24) Cell suspensions were centrifuged (1,200 × g, 10 minutes) and the cells were simultaneously stained with monoclonal mouse anti-human fluorochrome-conjugated antibodies: CD31-fluorescein isothiocyanate (FITC), CD34-FITC, CD90-FITC, CD140b-phycoerythrin (PE), CD146-PE, CD54-allophycocyanin (APC) (BD Biosciences), CD146-FITC, neuron-glial antigen 2 (NG2)-FITC, α-smooth muscle actin (αSMA)-PE, vascular endothelial growth factor receptor 2 (VEGFR2)-PE, C-X-C chemokine receptor type 4 (CXCR4)-PE, CD140b-APC (R&D systems), CD105-FITC, CD44-FITC (AbD Serotec, Kidlington, Oxford, UK), CD14-PE, CD45-PE (Dako), CD13-FITC (Novus Biological, Littleton, CO, USA), CD133-APC (Miltenyi Biotec, Auburn, CA, USA), and unconjugated antibodies (Desmin; Abcam, Cambridge, MA, USA). Analytical samples were fixed with 1% paraformaldehyde (PFA) for 10 minutes at RT. Four-color, 6-parameter data files were acquired on a 2-laser FACSCalibur flow cytometer (BD Biosciences) at a maximum of 10,000 events per second.
Cell sorting was performed using a 3-laser FACSAria II cell sorter (BD Biosciences).
Unfixed CD140b-PE stained samples were suspended in PBS, and 0.5% bovine serum albumin (BSA). Samples were continuously cooled to 4°C and single cell sorting was performed at 70,000 events per second. Samples were collected into BD Falcon round-bottom polypropylene tubes (BD Biosciences) containing 1 mL of DMEM/ Nutrient Mixture F-12 (DMEM/F12; Gibco) and plated in tissue culture dish (TPP; Techno Plastic Products, Trasadingen, Switzerland) at a density of 10,000 to 20,000 cell/ cm 2 . Adherent sorted and unsorted cells were expanded in equal volumes of DMEM/F12 and supplemented with 10% FBS, and 100 U/mL penicillin (Sigma-Aldrich).
Matrigel Tube Formation Assay
We evaluated the pericytic function of PDGFRβ+ cells that were collected from cultured ADSCs using FACS. We seeded human umbilical vein endothelial cells (HUVECs) and PDGFRβ+ ADSCs on the surface of a 100% Matrigel (BD Biosciences) in Endothelial Cell Growth Medium 2 (EGM2; Sigma-Aldrich) as previously reported. 25) Briefly, Matrigel was added to a 24-well plate followed by incubation for 30 minutes at 37°C. PDGFRβ+ cells (passage 2) and HUVEC were labeled with anti-von Willebrand factor (vWF; Abcam) and anti-CD140b (PDGFRβ, BD Biosciences). They were then detached from the culture plate by trypsin and seeded onto the Matrigel in DMEM/F12 culture medium at a ratio of 1:1. In total, 1 × 10 5 cells were seeded in each well of 24-well plates. Capillary tube formation was investigated after five hours by fluorescence microscopy (IX51; Olympus), inverted microscopy (IX50; Olympus) and confocal laser scanning microscope (TCS SP8; Leica Microsystems) microscopy.
Multilineage Differentiation Assay
For osteogenesis, cells at 70% confluence were cultivated in DMEM, 10% FBS, 0.1 mM dexamethasone, 50 mg/mL L-ascorbic acid, and 10 mM b-glycerophosphate. After 14 days, cells were fixed in citrate fixative (citrate solutionacetone-37% formaldehyde) for 1 minute. For detection of alkaline phosphatase (ALP) activity, the fixed cells were incubated for 15 minutes in a mixture of Naphthol AS-BI alkaline solution (Sigma-Aldrich). Cells were then rinsed with deionized water and mounted in GVA aqueous mounting solution (Genemed, San Francisco, CA, USA).
For chondrogenesis, pellets were prepared by spinning down 3 × 10 5 cultured cells and grown in serum-free DMEM containing an insulin-transferrin selenious acid mix (Sigma-Aldrich), 50 mg/mL L-ascorbic acid 2-phosphate (Sigma-Aldrich), 100 mg/mL sodium pyruvate, 40 mg/mL L-proline (Sigma-Aldrich), 0.1 mM dexamethasone (Sigma-Aldrich), and 10 ng/mL transforming growth factor beta 1 (TGF-β1; R&D Systems). After 21 days, pellets were fixed in 10% formalin, dehydrated in ethanol, and embedded in paraffin. For the Safranin O staining, specimen sections (thickness, 6 μm) were deparaffinized with xylene and ethanol and Safranin O solution (SigmaAldrich) was applied for 5-10 minutes.
For adipogenic differentiation, cultured cells at 70% confluence were switched to DMEM, 10% FBS, 1 mM dexamethasone, 0.5 mM isobutylmethylxanthine, 60 mM indomethacin, and 170 mM insulin (Sigma-Aldrich). After 21 days, cells were fixed in 5% PFA at RT, washed in PBS, and incubated with oil red O for 10 minutes at RT for the detection of lipids.
Statistical Analysis
All data are expressed as means ± standard deviations. Mann-Whitney U-test was used to compare branch points and tube numbers in Matrigel assay. IBM SPSS ver. 22.0 (IBM Co., Armonk, NY, USA) was used for the statistical analysis, and probability values of less than 0.05 were con- 
RESULTS
PDGFRβ+ Cells Located in the Perivascular Area Coexpressed MSC-Like Markers in the Small Arterioles of Fresh Human White Adipose Tissue
White adipose tissue from the subcutaneous fat of the human lower leg is a richly vascularized tissue (Fig. 1A) .
Immunofluorescence staining using endothelial (CD31) and pericyte markers (PDGFRβ and CD146) showed the exclusively perivascular location of PDGFRβ+ cells in various sizes of the blood vessels (small artery, arteriole, and capillary) (Fig. 1B-D) . Co-staining with a mesenchymal marker (CD90) showed that perivascular PDGFRβ+ cells also expressed mesenchymal markers in small arterioles ( Fig. 1C and D) , while CD90-positive cells and PDGFRβ+ cells were mutually exclusive in larger arteries (Fig. 1B) . (Fig. 2) .
24)
The CD45-positive cells are thought to include a mixture of leukocytes contained within the vasculature as well as cells resident in the adipose tissue. 24) Staining of freshly isolated cells for PDGFRβ and other markers showed that there was a substantial number of perivascular mesenchymal stem-like (PDGFRβ+/CD90+/CD44+/ CD45-) cell fractions in fresh SVF of human adipose tissue.
Culturing Isolated Cells from SVF on an Uncoated Tissue Culture Plastic Resulted in Providing Enrichment to the Perivascular Mesenchymal Stem-Like (PDGFRβ+/CD90+/CD45-) Cell Fractions
Plating of isolated cells from SVF on an uncoated tissue culture plastic resulted in selective adherence of cell population. Multilabel flow cytometric analysis of cultureexpanded ADSCs revealed that FACS analysis from fresh SVF of human adipose tissue showed that a population of endothelial (CD31 and CD144) and leukocytic (CD45) marker-positive cells was greatly reduced (Fig. 3) . Cultured PDGFRβ+ cells maintained the properties of PDGFRβ+ cells from fresh SVF except that they had a lower level of stem cell marker (CD34 and CXCR4)-positive cells. Cultured PDGFRβ+ cells expressed high levels of mesenchymal markers (CD13, CD44, CD54, and CD90), and a pericyte marker (αSMA). However, they expressed neither the endothelial markers (CD31 and CD144) nor the leukocytic marker (CD45).
24)
PDGFRβ+ Cells Were Located in the Perivascular Niche during Endothelial Tube Formation
When PDGFRβ+ ADSCs were cocultured with HUVEC, they demonstrated the formation of a tubular network (Fig.  4A ). Tube number was higher (124.5 ± 13.2 per plate, p < 0.05) than that formed by HUVEC (97.5 ± 5.5) or ADSC (62.8 ± 5.6) only. At a higher magnification, they showed a pericytic location, where PDGFRβ+ ADSCs adhered to HUVEC (Fig. 4B) . These results suggested that PDGFRβ+ ADSCs indeed possess a pericytic phenotype and stabilize the vascular tube-like network formed by HUVEC.
PDGFRβ+ Cells Displayed a Good Multilineage (Osteogenic, Chondrogenic, and Adipogenic) Differentiation Potential
To examine whether these cells have a multilineage differentiation ability, PDGFRβ+ cells were induced to differentiate into the osteogenic, chondrogenic, and adipogenic lineages. During the analysis for osteogenic differentiation assayed by ALP staining, the PDGFRβ+ cells showed greater ALP staining (Fig. 5A) . On the chondrogenic differentiation potential, verified by Safranin O staining, the PDGFRβ+ cells showed greater chondrogenic differentiation (Fig. 5B) . After adipogenic induction for 3 days, the cell morphology changed from long spindle-shaped into a round or polygonal shape (data not shown). One week later, small bubble-shaped oil red O-staining lipid droplets appeared in some parts of the cells. The size of lipid droplets increased after 2 weeks, and most of the differentiated cells showed red lipid droplets throughout the cytoplasm (Fig. 5C ). These results demonstrate that PDGFRβ+ cells have a multi-lineage differentiation ability.
DISCUSSION
In this study, we demonstrated that PDGFRβ+ cells are located in the perivascular area in fresh white adipose tissues of CLI patients and they coexpressed the MSC-like markers. We also showed that PDGFRβ+ cells from the CLI, an end stage of lower limb ischemia due to PAD is considered as one of the main targets for cell therapy using stem cells and progenitor cells based on promising experiences with BM-MNCs, [3] [4] [5] [6] [7] PB-MNCs, 8, 9) and ADSCs. 1, 10) Recently, the perivascular niche was discovered to be an important reservoir of MSCs in multiple developed organs (brain, spleen, liver, kidney, kidney glomeruli, lung, bone marrow, muscle, thymus, and pancreas), irrespective of their embryonic origin. 14, 15, 26, 27) Several studies have shown that cell populations obtained from the perivascular tissue exhibited the capacity of prolonged self-renewal and differentiated along mesenchymal cell lineages, making them defined as MSCs. 24, [28] [29] [30] Although perivascular progenitor cells are ubiquitous multipotent progenitors, isolation of perivascular progenitor cells for clinical application is not feasible from all human organs. 18) Adipose tissue represents an attractive source of autologous adult stem cells for regenerative therapy owing to its abundance, surgical accessibility, and high content of multipotent MSCs.
11) However, the development of an in vivo progenitor for culture-expanded MSC-like ADSCs remains elusive because of the complex organization of stromal cells surrounding the small vessels. 13) Coexpression of MSC-like markers in perivascular PDGFRβ+ cells suggests that perivascular niche could be an important reservoir of MSCs in white fat tissue, even in CLI patients. Traktuev et al. 24) have shown that multipotent adipose-derived stromal cells (ASCs) also have a perivascular location and express pericyte markers. They showed that ASCs express the pericyte markers including CD140a, CD140b, NG2, and αSMA, and occasionally express CD146. The highly defined ASC population (CD34+/ CD140a+/CD140b+/CD31-/CD45-/CD117-/CD144-) is the subset of adipose-derived cells, which possesses a majority of pericytic properties in the quiescent adipose tissue while harboring the ability to differentiate into multiple distinct lineages.
This study also demonstrates that PDGFRβ+ perivascular cells from ischemic adipose tissue have a good multilineage (osteogenic, chondrogenic and adipogenic) differentiation potential. However, the reason that neovascularization was inhibited in an ischemic condition in CLI patients with abundant PDGFRβ+ ADSC reservoirs is not clear. Further research needs to be performed to discover the signal that can awaken the PDGFRβ+ ADSC reservoir in CLI patients.
We carefully postulate that PDGFRβ+ cells from the SVF of adipose tissue can be used as a source of stem cells for autologous cell based treatment in CLI patients because (1) PDGFRβ+ cells in the SVF of adipose tissues are abundant and proliferative even in chronic CLI In conclusion, we demonstrated that pericyte-like PDGFR-positive cells from the SVF of adipose tissue from CLI patients might have the potential to enhance vascularization. We also found that they could be amplified and cells characteristics could be preserved in in vitro culture. Considering the pericytic localization of PDGFRβ+ ADSCs and their direct contact with endothelial cells, PDGFRβ+ cells in the SVF of adipose tissue can be used as a source of stem cells for autologous cell-based treatment in CLI patients.
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